相关实验视频

Updated: Feb 2, 2026

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors

Published on: August 18, 2023

独特的瘤免疫微环境 (TIME) 景观在质母细胞瘤中驱动不同的免疫疗法反应

Linqian Weng^1,2, Krish Skandha Gopalan^1,2, Mélanie Guyot^1,2

¹Laboratory of Tumor Microenvironment and Therapeutic Resistance, VIB-KU Leuven Center for Cancer Biology, Leuven, Belgium.

|January 31, 2026

概括

质母细胞瘤 (GBM) 有三个免疫微环境 (TIME) 亚型. 将免疫疗法定制为适合这些TIME亚型,特别是TIME-med,可以提高GBM治疗的疗效.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
癌症生物学癌症生物学

背景情况:

免疫疗法在质母细胞瘤 (GBM) 中表现出有限的成功.
合理定制免疫疗法需要了解瘤免疫微环境 (TIME) 和GBM中的血管景观.

研究的目的:

为了在GBM中功能地分类TIME和相关的血管景观.
调查GBM免疫治疗的亚型特定治疗策略.

主要方法:

使用单细胞/核RNA测序,多重免疫组织化学和流细胞计.
在人类和小鼠GBM模型中定义了TIME亚型.
在GBM小鼠模型中评估了对抗血管生成和免疫调节剂的治疗反应.

主要成果:

确定了三种不同的GBM TIME亚型 (TIME-low,TIME-med,TIME-high),具有独特的血管免疫特征.
经过时间测试的GBM对抗血管性免疫调节疗法的反应最为有利.
时间低的GBM表现出暂时的反应,而时间高的GBM在某些疗法下具有抗性或恶化,突出显示了针对骨髓细胞的策略的必要性.

结论:

GBM包括三种功能性时间亚型,需要特定于亚型的治疗方法.
随着时间的推移,GBM对当前的免疫疗法反应最好.
有效的GBM治疗需要针对特定的TIME特征,包括TIME高瘤中的骨髓性免疫抑制.

关键词:

抗血管性疗法是一种抗血管性疗法.质母细胞瘤 (glioblastoma) 是一个免疫治疗是一种免疫疗法.单细胞RNA测序的一个细胞.瘤免疫微环境 (TIME) 亚型

更多相关视频

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments

Published on: April 30, 2021

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Humoral Immune Responses

Humoral Immune Responses

Cell-mediated Immune Responses

Cell-mediated Immune Responses

Cells of the Adaptive Immune Response

Cells of the Adaptive Immune Response

The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...

Immune Response Against Viral Pathogens

Immune Response Against Viral Pathogens

The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...

Cells of the Innate Immune Response

Cells of the Innate Immune Response

The innate immune response is an immediate and non-specific response against pathogens, acting swiftly to prevent the spread of infections. The primary cells involved in this response are phagocytes and natural killer (NK) cells.
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...